Correction: Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study.

[This corrects the article DOI: 10.1371/journal.pone.0220435.].

RCT Entities:   Population Interventions Outcomes

Due to a typesetting error, incorrect versions of Fig 3 and its corresponding caption are included in this article [1]. The publisher apologizes for the error. Please see the correct Fig 3 and caption here.

Fig 3

Pattern electroretinogram (PERG) and visual evoked potentials (VEP) P100 implicit time recorded in response to 15’ checks (15’) results.

(A) Mean of absolute PERG P50-N95 Amplitude values observed in NC and NN Groups. * = ANOVA, p<0.01 in NN and NC Groups with respect to baseline. Vertical lines: one mean standard deviation. The statistical evaluation is reported in S2 Table. (B) Individual PERG P50-N95 Amplitude values observed in NC eyes at baseline plotted as a function of the values of the corresponding differences at the end of treatment (6 months minus baseline). Pearson’s test was used for regression analysis and linear correlation. (C) Mean of absolute VEP P100 implicit time values observed in NC and NN Groups. * = ANOVA, p<0.01 in NN and NC Groups with respect to baseline. Vertical lines: one mean standard deviation. Statistical evaluation is reported in “S2 Table”. (D) Individual VEP P100 implicit time values observed in NC eyes at baseline plotted as a function of the values of the corresponding differences at the end of treatment (6 months minus baseline). Pearson’s test was used for regression analysis and linear correlation.